"Visit the UCLA Health website for coronavirus updates."

During the past decade, UCLA CARE Center CRS conducted 43 clinical trials. In the 10-year time frame, 43 clinical trials started and 43 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 18 clinical trials started and 19 clinical trials were completed. i.e. 105.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "UCLA CARE Center CRS" #1 sponsor was "National Institute of Allergy and Infectious Diseases (NIAID)" with 121 trials, followed by "AIDS Clinical Trials Group" with 21 trials sponsored, "AIDS Malignancy Consortium" with 21 trials sponsored, "University of California, Los Angeles" with 10 trials sponsored and "National Cancer Institute (NCI)" with 10 trials sponsored. Other sponsors include 29 different institutions and companies that sponsored additional 26 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "UCLA CARE Center CRS" #1 collaborator was "National Institute of Allergy and Infectious Diseases (NIAID)" with 23 trials as a collaborator, "National Cancer Institute (NCI)" with 21 trials as a collaborator, "The Emmes Company, LLC" with 17 trials as a collaborator, "University of Arkansas" with 9 trials as a collaborator and "Glaxo Wellcome" with 8 trials as a collaborator. Other collaborators include 77 different institutions and companies that were collaborators in the rest 59 trials.

According to Clinical.Site data, the most researched conditions in "UCLA CARE Center CRS" are "HIV Infections" (143 trials), "HIV Infection" (20 trials), "HIV-1 Infection" (13 trials), "Hepatitis C" (9 trials) and "Sarcoma, Kaposi" (9 trials). Many other conditions were trialed in "UCLA CARE Center CRS" in a lesser frequency.

Most popular intervention types in "UCLA CARE Center CRS" are "Drug" (165 trials), "Biological" (34 trials), "Other" (27 trials), "Genetic" (10 trials) and "Procedure" (5 trials). Other intervention types were less common.

The name of intervention was led by "Zidovudine" (29 trials), "Lamivudine" (14 trials), "Stavudine" (13 trials), "Didanosine" (12 trials) and "Ritonavir" (12 trials). Other intervention names were less common.

The vast majority of trials in "UCLA CARE Center CRS" are 199 trials for "All" genders, 9 trials for "Male" genders and 8 trials for "Female" genders.

Currently, there are NaN active trials in "UCLA CARE Center CRS". 1 are not yet recruiting, 12 are recruiting, 10 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 176 completed trials in UCLA CARE Center CRS, 3 suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in UCLA CARE Center CRS, 44 "Phase 1" clinical trials were conducted, 90 "Phase 2" clinical trials and 45 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 9 trials, and there were also 21 trials that are defined as “Not Applicable".

UCLA CARE Center CRS has several departments that took part in Clinical trials: "UCLA Division of Hematology Oncology" - 9 trials, "Westwood Bowyer Clinic, Peter Morton Medical Building" - 5 trials, "AIDS Clinical Research Ctr / UCLA Med Ctr" - 2 trials